缺血性脑血管病溶栓治疗临床研究

Clinical study on thrombolytic therapy in treating ishemic cerebrovascular disease

本文将150例缺血性脑血管病患者分为尿激酶(urokinase,UK)治疗组与精制蝮蛇抗栓酶(SVATE-3)组(对照组)。UK组的治疗总有效率高于对照组(P值分别<0.05,0.01)。尤其是发病后12小时内开始应用UK组的治疗总有效率明显高于对照组(P<0.01),提示早期应用UK是治疗缺血性脑血管病、降低病死率、提高生存质量的关键。

150 cases ischemic cerebravascuiar disease were dividied in four groups: two UKgroups and two svate-3 groups (controls). UKgroups treated with UK did show better curative effects (P< 0.05 and P<0. 01). Especially, UKgroup treated during 12 hours after the onset of acute ischemic stroke was significantly higher effective rate than that in the control group (P<0. 01). Treated with UK done soon after the onset of ischemic stroke is crucial in lowering its mortality and in improving quality of life after recovry.